Black phosphorus quantum dot based novel siRNA delivery systems in human pluripotent teratoma PA-1 cells

2017 ◽  
Vol 5 (27) ◽  
pp. 5433-5440 ◽  
Author(s):  
Feng Yin ◽  
Kuan Hu ◽  
Si Chen ◽  
Dongyuan Wang ◽  
Jianing Zhang ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Quantum Dot ◽  
Transfection Efficiency ◽  
Sirna Delivery ◽  
Delivery Systems ◽  
Black Phosphorus ◽  
Semiconducting Materials ◽  
Photothermal Effects ◽  
Low Cytotoxicity

As a novel semiconducting materials, BP-QDs possess superior transfection efficiency, excellent biocompatibility and low cytotoxicity, which shows promising potential for siRNA delivery and photothermal effects in cancer therapy.

Progresses in microRNA Delivery Using Synthetic Nanovectors in Cancer Therapy

2019 ◽  
Vol 24 (31) ◽  
pp. 3678-3696 ◽  
Author(s):  
Sanaz Javanmardi ◽  
Mahmoud Reza Aghamaali ◽  
Samira Sadat Abolmaali ◽  
Ali Mohammad Tamaddon
Keyword(s):  
Gene Expression ◽  
Cancer Therapy ◽  
Pharmacological Action ◽  
Delivery Systems ◽  
Aberrant Expression ◽  
Small Noncoding Rnas ◽  
Anti Cancer ◽  
Low Cytotoxicity ◽  
Microrna Delivery ◽  
Endosomal Release

MicroRNAs are small noncoding RNAs with key roles in gene expression. It has been revealed that aberrant expression of microRNAs is related to gene expression abnormality, and they have the potential to be used as anti-cancer drugs. However, the delivery of microRNAs is limited due to barriers, such as low uptake and insufficient endosomal release, intracellular nucleases degradation, phagocytic elimination, and renal filtration. To overcome these issues, novel delivery systems are developed for improving the efficiency of microRNAs therapy ranging from viral to synthetic; some are further developed with targeted ligands for active targeting purposes. Such delivery systems provide efficient cellular uptake and endosomal release as well as low cytotoxicity and minimum unwanted host immune response. Nevertheless, more complementary studies are warranted before being applied in human studies. This review deals with recent updates on the challenges and achievements of the various nanotechnology-based gene delivery vehicles with a special emphasis on the miRNA delivery in cancer therapy. In addition, we attempted to categorize the designed delivery systems based on miRNA therapeutic molecule. The related cellular signaling pathways and pharmacological action against cancer promotion have also been highlighted.

Low molecular weight chitosan–protamine conjugate for siRNA delivery with enhanced stability and transfection efficiency

RSC Advances ◽  
2016 ◽  
Vol 6 (112) ◽  
pp. 110951-110963 ◽  
Author(s):  
Sushilkumar Patil ◽  
Priyanka Bhatt ◽  
Rohan Lalani ◽  
Jitendra Amrutiya ◽  
Imran Vhora ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Transfection Efficiency ◽  
Sirna Delivery ◽  
Low Molecular Weight ◽  
Low Molecular Weight Chitosan ◽  
Low Cytotoxicity ◽  
Enhanced Stability

Chitosan is among the few polymers with high biocompatibility and low cytotoxicity.

scholarly journals Non‐viral siRNA delivery systems for pancreatic cancer therapy

2021 ◽  
Author(s):  
Shahin Aghamiri ◽  
Pourya Raee ◽  
Sam Talaei ◽  
Samira Mohammadi‐Yeganeh ◽  
Shiva Bayat ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Therapy ◽  
Sirna Delivery ◽  
Delivery Systems ◽  
Pancreatic Cancer Therapy

scholarly journals Lipid and Polymer-Based Nanoparticle siRNA Delivery Systems for Cancer Therapy

Molecules ◽  
2020 ◽  
Vol 25 (11) ◽  
pp. 2692 ◽  
Author(s):  
Francesco Mainini ◽  
Michael R. Eccles
Keyword(s):  
Cancer Therapy ◽  
Gene Silencing ◽  
Sirna Delivery ◽  
Cancer Therapeutics ◽  
Delivery Systems ◽  
Fine Tuning ◽  
Host Cells ◽  
Specific Cell ◽  
Small Interfering Rnas

RNA interference (RNAi) uses small interfering RNAs (siRNAs) to mediate gene-silencing in cells and represents an emerging strategy for cancer therapy. Successful RNAi-mediated gene silencing requires overcoming multiple physiological barriers to achieve efficient delivery of siRNAs into cells in vivo, including into tumor and/or host cells in the tumor micro-environment (TME). Consequently, lipid and polymer-based nanoparticle siRNA delivery systems have been developed to surmount these physiological barriers. In this article, we review the strategies that have been developed to facilitate siRNA survival in the circulatory system, siRNA movement from the blood into tissues and the TME, targeted siRNA delivery to the tumor or specific cell types, cellular uptake, and escape from endosomal degradation. We also discuss the use of various types of lipid and polymer-based carriers for cancer therapy, including a section on anti-tumor nanovaccines enhanced by siRNAs. Finally, we review current and recent clinical trials using NPs loaded with siRNAs for cancer therapy. The siRNA cancer therapeutics field is rapidly evolving, and it is conceivable that precision cancer therapy could, in the relatively near future, benefit from the combined use of cancer therapies, for example immune checkpoint blockade together with gene-targeting siRNAs, personalized for enhancing and fine-tuning a patient’s therapeutic response.

scholarly journals Chitosan Combined with Poly-L-arginine as Efficient, Safe, and Serum-Insensitive Vehicle with RNase Protection Ability for siRNA Delivery

2013 ◽  
Vol 2013 ◽  
pp. 1-9 ◽  
Author(s):  
Samarwadee Plianwong ◽  
Praneet Opanasopit ◽  
Tanasait Ngawhirunpat ◽  
Theerasak Rojanarata
Keyword(s):  
Fluorescent Protein ◽  
Transfection Efficiency ◽  
Sirna Delivery ◽  
Weight Ratio ◽  
Deterrent Effect ◽  
Egfp Gene ◽  
Rnase Protection ◽  
Low Cytotoxicity ◽  
Green Fluorescent ◽  
Positively Charged

Chitosan (CS) combined with poly-L-arginine (PLA) was formulated and evaluated for its performance to deliver siRNA to HeLa cells expressing enhanced green fluorescent protein (EGFP). Compared with the formulations using single polymer in which the polyplexes were completely formed at the weight ratio of >20 : 1 for CS/siRNA or 1 : 1 for PLA/siRNA, the combination of CS and PLA could reduce the amounts of the polymers required for the complete complexation with siRNA, thereby forming positively charged, nanosized polyplex at the weight ratio of CS/PLA/siRNA of 5 : 0.5: 1. In addition, while the transfection efficiency of CS/siRNA and PLA/siRNA was very low at physiological pH (7.4), CS/PLA/siRNA at the optimal weight ratio of 5 : 0.5 : 1 satisfactorily silenced the endogenous EGFP gene at pH 7.4 as well as at pH 6.4 without the deterrent effect from serum. The combined polymers could protect siRNA from RNase degradation over a period of at least 6 h. Furthermore, MTT assay results demonstrated that CS/PLA/siRNA complexes showed acceptably low cytotoxicity with 75% cell viability. Therefore, CS combined with PLA is easy to prepare, safe, and promising for use as an efficient siRNA delivery vehicle.

scholarly journals Nanoparticle‐mediated siRNA delivery systems for cancer therapy

View ◽  
2021 ◽  
pp. 20200111
Author(s):  
Han Gao ◽  
Ruoyu Cheng ◽  
Hélder A. Santos
Keyword(s):  
Cancer Therapy ◽  
Sirna Delivery ◽  
Delivery Systems

Biomedical application of chitosan-based nanoscale delivery systems: Potential usefulness in siRNA delivery for cancer therapy

2021 ◽  
Vol 260 ◽  
pp. 117809
Author(s):  
Milad Ashrafizadeh ◽  
Masoud Delfi ◽  
Farid Hashemi ◽  
Amirhossein Zabolian ◽  
Hossein Saleki ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Biomedical Application ◽  
Sirna Delivery ◽  
Delivery Systems ◽  
Potential Usefulness

Use of Lipids, Polymers, and Peptides for Drug Delivery and Targeting to Cancer Cells or Specific Organs

2021 ◽  
pp. 276-289
Author(s):  
Sampan Attri ◽  
Shruti Sharma ◽  
Ujjawal Sharma ◽  
Manjita Srivastava ◽  
Subash C. Sonkar ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Cancer Therapy ◽  
Drug Delivery Systems ◽  
Structural Characteristics ◽  
Delivery Systems ◽  
Chemotherapeutic Agents ◽  
Delivery Methods ◽  
Practical Applications ◽  
Low Cytotoxicity

Cancer has been the most deleterious disease in recent times, and unfortunately its spread is increasing. Systemic treatment with chemotherapeutics remains the conventional way of treating many cancers, despite the serious damage long-term chemotherapy can cause in healthy tissues. Many therapeutic strategies have achieved popular practical applications, but drug delivery systems still face challenges associated with safety, and this has led to the development of safer drug delivery methods composed of biocompatible substances. In this respect, lipid-, polymer-, and peptide-based drug delivery systems have been proposed as safer candidates for cancer therapy. These delivery methods are expected to as biodegradable systems with low cytotoxicity for cancer therapy. Therefore, in this chapter, the authors discuss use of lipids, polymers, and peptides as delivery vehicles for chemotherapeutic agents and their structural characteristics.

scholarly journals siRNA Delivery Technology for Cancer Therapy: Promise and Challenges

2019 ◽  
Author(s):  
Fateme Karimi Dermani ◽  
Farid Azizi Jalilian ◽  
Hossein Hossienkhani ◽  
Razieh Ezati ◽  
Razieh Amini
Keyword(s):  
Cancer Therapy ◽  
Sirna Delivery ◽  
Delivery Systems ◽  
Therapeutic Interventions ◽  
Great Promise ◽  
Specific Gene ◽  
Small Interfering Rnas ◽  
Systemic Delivery ◽  
New Class ◽  
Delivery Technology

Abstract- Small interfering RNAs (siRNA) technology has shown great promise as a new class of therapeutic interventions for the treatment of cancer and other diseases. It is a remarkable endogenous pathway that can regulate sequence-specific gene silencing. Despite the excitement about possible applications of this biological process for sequence-specific gene regulation, the major limitations against the use of siRNA-based therapeutics are their rapid degradation by serum nuclease, poor cellular uptake, and rapid renal clearance following systemic delivery, off-target effects and the induction of immune responses. Many researchers have tried to overcome these limitations by developing nuclease-resistant chemically-modified siRNAs and a variety of synthetic and natural biodegradable lipids and polymers to enhance the efficacy and safety profiles of siRNA delivery. Ideal siRNA-based delivery systems for cancer therapy must be clinically suitable, safe and effective. In this review, we introduce the greatest challenges in achieving efficient RNAi delivery and discuss design criteria and various delivery strategies for cancer therapy, including chemical modifications, lipid-based nano-vectors, polymer-mediated delivery systems, conjugate delivery systems, and others.

Sign in / Sign up

Export Citation Format

Share Document